Organisation
Hepatology
Division
The labo of Hepatology studies pathophysiology and treatment of liver and pancreas diseases and metabolism.
Current researchers
1 - 10 of 15 results
- Schalk Van der Merwe (Responsible)
- Isabelle Adant (Member)
- David Cassiman (Member)
- Rita Furtado Feio De Azevedo (Member)
- Hannelie Korf (Member)
- Wim Laleman (Member)
- Louis Libbrecht (Member)
- Frederik Nevens (Member)
- Lukas Van Melkebeke (Member)
- Marc Van de Casteele (Member)
Projects
1 - 10 of 50
- Unravelling aberrant host-microbiota interactions underlying intestinal epithelial barrier failure in cirrhosisFrom7 Feb 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Harnessing single-cell and spatial transcriptomics to uncover novel insights into the pathological events that trigger the progression of acute-on-chronic liver failureFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Harnessing Single-Cell and Spatial Transcriptomics to Uncover Novel Insights into Intestinal Barrier Breach in CirrhosisFrom1 Oct 2023 → TodayFunding: Fund Recuperation Fiscal Exemption, BOF - projects
- Exploring the molecular mechanisms underlying bacterial translocation in cirrhosisFrom29 Sep 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Harnessing single-cell and spatial transcriptomics to uncover novel insights into the pathological events that trigger the progression of acute-on-chronic liver failureFrom1 Sep 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Validation and implementation of a prognostic biomarker of early graft failure after liver transplantation (GlycoTransplantTest)From1 Oct 2022 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Model-informed precision dosing of tacrolimus in solid organ transplant recipientsFrom27 Jul 2022 → TodayFunding: FWO Strategic Basic Research Grant
- Design of robotic catheter and endoscopic systems for cancer treatmentFrom16 Feb 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Stratifying risk and individualizing care for patients with clinically significant portal hypertension (CSPH)From7 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Metabolic rewiring in SORDD polyneuropathy: unraveling a polyol pathway disorderFrom1 Oct 2021 → TodayFunding: FWO fellowships
Publications
31 - 40 of 1341
- EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis(2018)
Authors: European Association for the Study of the Liver, European Association for the Study of the Liver, C Villanueva, C Francoz, RP Mookerjee, J Trebicka, A Krag, Wim Laleman, P Gines
Pages: 406 - 460 - Acute liver failure: current european perspective(2010)
Authors: J Wendon, M Manns, G Alexander, M Aldersley, A Burroughs, K Simpson, D Mutimer, Frederik Nevens, W Bernal, P -F Laterre, et al.
Pages: S13 - S14 - DERIVATION OF A MACHINE LEARNING MODEL TO PREDICT CLINICAL OUTCOME IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS(2019)
Authors: Jorn Goet, Surain Roberts, Gideon Hirschfield, Pietro Invernizzi, Marco Carbone, Palak Trivedi, Christophe Corpechot, Harry LA Janssen, Rozanne de Veer, Willem J Lammers, et al.
Pages: 760A - 761A - WHEN IS INTENSIVE CARE TREATMENT FUTILE IN PATIENTS WITH ORGAN FAILURE AND END-STAGE LIVER DISEASE?(2016)
Authors: KP Lindvig, M Thiele, V Fuhrmann, Wim Laleman, K Roedl, Len Verbeke, K Faber, T Strom, J O'Beirne, P Toft, et al.
Pages: S166 - S166 - Everolimus-Facilitated reduction of Tacrolimus provides comparble efficacy and superior renal function versus standard tacrolimus in de novo liver transplant recipients: 24-month results of a randomized trial(2012)
Authors: Frederik Nevens
Pages: 2 - 2 - The First New Trials for Primary Biliary Cirrhosis in a Decade: An International Program Evaluating the Farnesoid X Receptor Agonist Obeticholic Acid(2015)
Authors: Kris y Kowdley, Frederik Nevens, Pietro Andreone, Velimir A Luketic, Hemant Shah, Richard Pencek, Tonya K Marmon, David Shapiro
Pages: S991 - S992 - Everolimus Based Immunosuppression in Hepatitis C Virus Positive De Novo Liver Transplant Recipients: 24 Month Results from a Randomized Controlled Trial(2013)
Authors: F Saliba, Jr Brown, H Metselaar, S Beckebaum, C Duvoux, M Navasa, G Dong, P Lopez, Frederik Nevens
Pages: S100 - S101 - Acute-on Chronic Liver Failure (ACLF): A distinct clinical syndrome(2012)
Authors: Rajiv Jalan, Richard Moreau, Pere Gines, Marco Pavesi, Paolo Angeli, Paolo Caraceni, Corinna Hopf, Carlo Alessandria, Pablo Solis-Munoz, Wim Laleman, et al.
Pages: 249A - 249A - VALIDATION OF AN ALKALINE PHOSPHATASE AND BILIRUBIN RESPONSE CRITERION AS BIOMARKER FOR TRANSPLANT-FREE SURVIVAL IN PRIMARY BILIARY CIRRHOSIS IN THE WORLD'S TWO LARGEST COHORTS(2015)
Authors: M Carbone, MH Harms, K Lindor, GM Hirschfield, WJ Lammers, M Heneghan, HL Janssen, JM Neuberger, D Thorburn, A Pares, et al.
Pages: S782 - S783 - Efficacy and safety of everolimus with early reduction or elimination of tacrolimus in 719 de novo liver transplant recipients: 12 month results of a phase iii, randomized, controlled study(2011)
Authors: Faouzi Saliba, Paolo De Simone, Frederik Nevens, Luciano De Carlis, Herold Metselaar, Susanne Beckebaum, Sven Jonas, Debra Sudan, Lutz Fischer, John J Fung, et al.
Pages: 1430